Heron Therapeutics HRTX 深 滬
等待開盤 10-23 09:30:00 美东时间
1.19
-0.110
-8.46%
華盛通- 最 高1.31
- 今 開1.30
- 成交量 258.60万股
- 最 低 1.17
- 昨 收 1.30
- 總市值 2.18亿
- 52周最高 2.68
- 市盈率 靜 --
- 換手率 1.41%
- 52周最低 1.04
- 委 比 15.15%
- 總股本 1.83亿
- 歷史最高 42.90
- 量 比 2.43
- 振 幅 10.77%
- 歷史最低 0.16
- 每 手 1
- 風險率 0.79%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Heron Therapeutics to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025
Heron Therapeutics will hold a conference call and webcast on November 4, 2025, at 8:30 a.m. ET to discuss Q3 2025 financial results and recent business highlights. Participants can access the call via a registration link or through Heron's website under the Investor Relations section. An archive will be available post-call. Heron is a biotech company focused on improving patient care through innovative therapeutic developments.
10-21 20:20
Heron Therapeutics Approves Stock Issuance Proposals
Heron Therapeutics ( ($HRTX) ) has issued an announcement. On October 13, 2025,...
10-16 04:29
Heron Therapeutics Signs New Headquarters Lease
Heron Therapeutics ( ($HRTX) ) has shared an update. Heron Therapeutics, Inc. h...
08-29 05:30
HeartCore Regains Compliance with Nasdaq Minimum Stockholders’ Equity Requirement
HeartCore Enterprises Inc., a leading enterprise software and consulting services company, announced that it has regained compliance with the $2.5 million minimum stockholders’ equity requirement for continued listing on the Nasdaq Capital Market. This determination was based on the company’s June 30, 2025, quarterly report, which reported stockholders’ equity of $3,559,017. HeartCore provides SaaS solutions, data analytics services, customer exp...
08-28 12:30
Heron Therapeutics Adopts Tax Benefit Preservation Plan
The latest announcement is out from Heron Therapeutics ( ($HRTX) ). On August 1...
08-15 20:24
Heron Therapeutics Signs Agreement with Patheon
An announcement from Heron Therapeutics ( ($HRTX) ) is now available. On August...
08-13 05:12
美股大行评级 | 潜在涨幅286.44%！RBC Capital上调Edgewise Therapeutics目标价至49美元，维持"跑赢大市"评级
今日重点评级关注：RBC Capital：维持Edgewise Therapeutics"跑赢大市"评级，目标价从48美元升至49美元；RBC Capital：维持Nuvation Bio"跑赢大市"评级，目标价从6美元升至7美元
08-11 09:43
Needham Maintains Buy on Heron Therapeutics, Lowers Price Target to $3
Needham analyst Serge Belanger maintains Heron Therapeutics (NASDAQ:HRTX) with a Buy and lowers the price target from $4 to $3.
08-09 03:01
Heron Therapeutics shares are trading lower after the company reported worse-than-expected Q2 financial results.
Heron Therapeutics shares are trading lower after the company reported worse-th...
08-08 20:57
